This is an observational survey to assess the factors that influence adherence to Betaferon therapy in multiple sclerosis patients using elements of the BetaPlus support program, including the nurse support and auto-injectors. The patients were evaluated under normal clinical practice and were asked to fill out the quality of life FAMS questionnaire, Coping processes (WCQ) and depression questionnaire CES-D.
Study Type
OBSERVATIONAL
Enrollment
10
250 µg, sub-cutaneously, on alternate days
Unnamed facility
Many Locations, Portugal
Identification of reasons why patients are switched from other disease modifying drugs to Betaferon due to perceived lack of efficacy, adverse events, poor compliance, and others.
Time frame: After 2 years
Assessment of factors predictive of non-adherence to disease modifying drugs such as demographic data, course of disease, drug history, patients characteristics, history of poor compliance to prior therapy or others.
Time frame: After 2 years
Assessment of impact of supportive elements of the BetaPlus Program like nurse support, auto-injector, website, etc on treatment adherence.
Time frame: After 2 years
Evaluation of impact of Betaferon treatment on health related quality of life using the Functional Assessment of Multiple Sclerosis Questionnaire - FAMS.
Time frame: After 2 years
Assessment of coping processes by applying the Ways of Coping Questionnaire.
Time frame: After 2 years
Measurement of safety of Betaferon by assessing the number of participants with adverse events and severe adverse events. Classification by MedDRA category.
Time frame: After 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.